Author: therawinformant

Yahoo Finance’s Dan Howley breaks down what investors can expect from the Zoom Video Communications earnings report after Tuesday’s closing bell.

from Yahoo Finance https://ift.tt/2XsuAHz

While the U.S. is facing an economic fallout, investors are feeling more pressure to save for their retirement. BlackRock Retirement Group Head Anne Ackerley joins Yahoo Finance’s On The Move to weigh in on the company’s new retirement initiative.

from Yahoo Finance https://ift.tt/2U5oDy2

Miami-Dade County High School Teacher Amy Scott joins Yahoo Finance’s On The Move panel to address how the COVID-19 pandemic is impacting teachers across the nation.

from Yahoo Finance https://ift.tt/2U28ABj

Penny stocks are controversial, to say the least. When it comes to these under $5 per share investment opportunities, Wall Street observers usually either love them or hate them. The penny stock-averse point out that while the bargain price tag is tempting, there could be a reason shares are trading at such low levels like poor fundamentals or insurmountable headwinds.However, the other side of the coin has merit as well. Naturally, with these cheap tickers, you get more bang for your buck in terms of the amount of shares. On top of this, other more expensive and well-known names aren’t as likely to produce the colossal gains that penny stocks are capable of.Given the nature of these investments, Wall Street analysts recommend doing some due diligence before pulling the trigger, noting that not all penny stocks are bound for greatness.With this in mind, we set out our own search for compelling investments that are set to boom. Using TipRanks’ database, we pulled three penny stocks that have amassed enough analyst support to earn a “Strong Buy” consensus rating. Adding to the good news, each pick boasts over 125% upside potential. Hyrecar, Inc. (HYRE)We all know about the gig economy, which turned the world of freelance work upside down by using the internet to connect people with skills to jobs that needed doing. And we all know how Airbnb used a similar model in the world of short-term lodging. Hyrecar brings the online sharing model to the automotive sector, allowing vehicle owners to rent out their cars short-term, even hourly; car owners can use their cars to make money during downtime, while car renters get the convenience of a vehicle right when they need it.Where many companies saw steep revenue drops in Q1, Hyrecar’s top line was healthy. Revenues grew 20% sequentially and 65% year-over-year, to reach $5.8 million. While EPS was negative, showing a 25 cent per share net loss, that was a 19% improvement from Q4’s 31-cent net loss. The solid revenue number and the EPS improvement were based on a 16% increase in rental days from Q4 to Q1.At $2.25, several analysts argue that now is the time to snap up shares. Ladenburg analyst Jon Hickman puts Hyrecar into the context of recent events, and likes the fit he sees: “Prior to early March, the company hit a weekly rental day high of more than 20,000 as vehicle supply continued to climb in line with the success of the Fleet initiative. In the days that followed (as the country shut down) through early April, weekly rental days fell to a level of 14,000, but have since begun to recover as the company focused its drivers on delivery opportunities… the company's concerted effort to help drivers sign up with such services as Door Dash, Instacart, and other delivery services (food and packages) has resulted in a notable uptick in weekly rental days, which is now trending toward 18,000.”Believing that HYRE’s best days are in front, and that the company will see continued growth into 2021, Hickman puts a Buy rating on the stock. His $5.25 price target suggests a one-year upside potential of 133%. (To watch Hickman’s track record, click here)Overall, Wall Street agrees that HYRE is a stock to buy. The Strong Buy analyst consensus is unanimous, based on 4 recent positive reviews, while the average price target, of $5.94, is actually more bullish than Hickman’s, implying a 171% upside potential in the coming year. (See Hyrecar stock analysis on TipRanks)Genco Shipping, Inc. (GNK)Next up is a small-cap shipping company, Genco. The company boasts a market cap of $207 million, along with a major asset: a modern fleet of dry bulk carriers. These ships, varying in size from 34,000-ton Handysize freighters to the giant 175,000+ ton Capemax vessels, are wholly owned and modern, with a majority of the fleet build in the past decade. Genco transports essential dry bulk cargoes such as coal, grain, iron ore, and steel around the world.The coronavirus pandemic, with its heavy impact on trade and travel, hit Genco hard in Q1. The company saw earnings plummet, and EPS registered a 17-cent loss per share in the first quarter, a sharp turn from Q4’s 7-cent profit. At the same time, the company was able to continue streamlining its operations, including selling off three of its least profitable vessels, and took action to improve its cash position. Genco finished the quarter with $134.3 million in unrestricted cash on hand, and is negotiating a further $25 million in collateralized credit from its main lenders.Despite the recent struggles, one analyst argues that the $4.94 price tag is a solid deal for investors.Writing on GNK stock for Evercore ISI, Jonathan Chappell said, “GNK still retains the strongest balance sheet in the dry bulk industry… GNK should be able to build upon its cash balance, enabling it to return to the prior dividend run rate once there is more clarity on the global economic backdrop and the timing on an eventual dry bulk market recovery, while its liquidity could also render it as the market consolidator if other less-well-capitalized owners fall victim to a prolonged global recession.”Chappell's numbers are upbeat, too. The $9 price target suggests a robust 82% upside potential, and fully supports his Buy rating on the stock. (To watch Chappell’s track record, click here)Chappell's bullish stance on Genco Shipping is in line with Wall Street’s view. GNK has a Strong Buy consensus rating, based on 4 Buy ratings and single Hold set in recent weeks. Meanwhile, the average price target of $10.80 leaves a room for nearly 119% upside from current levels. (See Genco stock analysis on TipRanks)Reed’s, Inc. (REED)Reed’s, a small cap company in the craft soda markets, is best known for its ginger ale and ginger beer products. The company’s eponymous brand and product line also extends to zero-sugar sodas and ginger candy. It’s a small niche, but one with a clear path forward: Reed’s reported a 13% year-over-year sales increase in Q1 2020. That sales increase translated into a $9.5 million top line. While EPS has been showing let losses for the past two years, those losses bottomed in Q3 2019; the Q1 number, a loss of 5 cents per share, represented the smallest loss in 9 quarters, and a 44% sequential improvement. Looking forward, the quarterly loss is expected to narrow further, to just 3 cents per share, in Q2. The positive outlook is buoyed by the 21% volume growth of the core Reed’s Ginger Ale brand in Q1.At only $0.68 per share, some members of the Street see an attractive entry point.Maxim analyst Anthony Vendetti writes of REED, “…the COVID-19 pandemic has resulted in some slight reset delays, it has also generated robust supermarket trends, creating increased demand for REED products in grocery stores. The company continues to expand its distribution network and has increased its manufacturing capacity… REED continues to enhance its supply chain, only experiencing minimal disruptions due to COVID-19.”Overall, based on "REED’s differentiated product offerings and continued progress," Vendetti stays with the bulls. That solid position underlies Vendetti’s Buy rating, while his $2 price target implies a whopping 194% upside potential for the year ahead. (To watch Vendetti’s track record, click here)Like the other stocks in this article, REED has a Strong Buy consensus – and it is based on 3 Buy ratings given in the past 3 months. The shares have an average price target of $2.33, suggesting a 243% upside from current levels. (See Genco stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

from Yahoo Finance https://ift.tt/2AzhQpq

Bristol Myers Squibb (BMY) has announced positive results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis.True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at Week 10 and in maintenance at Week 52.The study also met key secondary endpoints of clinical response and endoscopic improvement in induction at Week 10 and in maintenance at Week 52, BMY reported.At the same time, the safety profile of Zeposia in the True North trial was consistent with previously reported trials.BMY will now complete a full evaluation of the True North data and work with investigators to present detailed results at a future medical meeting, as well as discuss these results with health authorities.“Patients with ulcerative colitis can struggle to effectively manage this often unpredictable and potentially debilitating disease. The True North results are encouraging for patients… as Zeposia demonstrated consistency across key clinical and endoscopic endpoints,” stated BMY’s chief medical officer, Samit Hirawat, M.D.Ulcerative colitis, a chronic inflammatory bowel disease (IBD), is characterized by an abnormal, prolonged immune response that creates long-lasting inflammation and ulcers in the mucosa lining of the colon. It is estimated that 12.6 million people worldwide have IBD.Bristol Myers Squibb is also investigating Zeposia for the treatment of moderately to severely active Crohn’s disease in the ongoing Phase 3 Yellowstone clinical trial program. Zeposia is already approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults by the FDA and EMA.Shares in BMY are currently trading down 6% year-to-date. However, analysts have a bullish Strong Buy consensus on the stock with 4 recent buy ratings vs just 1 hold rating. Meanwhile the average analyst price target stands at $66 (9% upside potential). (See BMY stock analysis on TipRanks).Related News: Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A Efgartigimod’s Positive Data Is Good News for Momenta’s Nipocalimab More recent articles from Smarter Analyst: * Free Version of WWE Network Now Available for Fans * Pfizer Embarks On $500 Million Investment Plan For Biotech Businesses * MongoDB Earnings Preview: Analysts Looking For Beat, Raise Quarter * Lear Corporation Set to Reopen Plant After Coronavirus Outbreak Kills 20

from Yahoo Finance https://ift.tt/2Mo7MTa

Camden County, NJ Police Chief Joseph Wysocki joins Yahoo Finance’s Anjalee Khemlani and Zack Guzman to discuss why he marched in protests over the weekend in response to the death of George Floyd.

from Yahoo Finance https://ift.tt/3cnvGIM

In this article we will check out the progression of hedge fund sentiment towards Peloton Interactive, Inc. (NASDAQ:PTON) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

from Yahoo Finance https://ift.tt/2MoTRw0

Roku is updating its The Roku Channel with more streaming options, putting it closer to competition with the likes of Netflix and Disney.

from Yahoo Finance https://ift.tt/3csYgsc

U.S. drugmaker Pfizer Inc. (PFE) on Wednesday announced an initiative to invest up to $500 million in biotechnology companies to help provide funding for the industry’s most promising clinical development programs.The investment, which will be channeled through the establishment of the so-called Pfizer Breakthrough Growth Initiative, also seeks to ensure the continuity of the biotechs’ clinical development programs, the company said in a statement.“There has never been a more important moment to pursue new collaborations in our industry," said Pfizer's Chief Business Officer John Young. “The Pfizer Breakthrough Growth Initiative seeks to do just this by injecting crucial capital into biotechnology companies that share our commitment to delivering transformative therapies for patients.”The initiative will focus on making non-controlling equity investments in clinical-stage public companies. The primary focus will be on companies with small- to medium-sized market capitalizations across a range of therapeutic categories that are consistent with Pfizer’s core areas of focus: internal medicine, inflammation & immunology, oncology, rare disease, and vaccines.Potential partner companies will get access to Pfizer’s expertise and resources in research, clinical development and manufacturing.Pfizer said that the investment program builds on Pfizer’s long history of successfully collaborating across the healthcare innovation ecosystem, through a wide range of flexible partnering and funding models, with the shared goal of turning science into innovative new medicines.The announcement comes after the drugmaker reported a disappointing outcome for its Phase 3 PALLAS early breast cancer study sending shares down this week.The stock dropped 7.2% to $35.46 as of Monday’s close after it advanced some 30% since the end of March.Following the breast cancer study results, Barclays analyst Carter Gould trimmed the drugmaker’s price target to $35 from $37 and maintained a Hold rating on the shares.In view of Pfizer's disclosure that the Ibrance Phase 3 PALLAS study was being stopped for futility, Gould removed all adjuvant sales from the model, while also lowering his 2025 sales estimates by about $2 billion, and the 2020-2025 annual earnings growth estimate to 3.3% from 4.1%.Overall, Wall Street analysts are cautiously optimistic on Pfizer’s shares with 7 Hold and 3 Buy ratings. This gives the stock a Moderate Buy consensus with a $40.03 average price target (13% upside potential to current levels). (See Pfizer stock analysis on TipRanks).Related News: Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A Efgartigimod’s Positive Data Is Good News for Momenta’s Nipocalimab More recent articles from Smarter Analyst: * Free Version of WWE Network Now Available for Fans * Bristol Myers Reveals Positive Results For Ulcerative Colitis Pivotal Trial * MongoDB Earnings Preview: Analysts Looking For Beat, Raise Quarter * Lear Corporation Set to Reopen Plant After Coronavirus Outbreak Kills 20

from Yahoo Finance https://ift.tt/2AyYnVS

Visa (V) has indicated a solid uptick in consumer spending from April to May, as it continues to actively monitor the Covid-19 impact globally.Most notably, in May, total U.S. payments volume declined 5% year-over-year, a 13 percentage point (ppt) improvement over April. Meanwhile debit grew 12% and credit declined 21% year-over-year in May, a 17 ppt and 9 ppt improvement over April, respectively.“The continued distribution of Economic Impact Payments and the relaxing of shelter-in-place restrictions in a number of states are driving these trends” Visa stated.However, recovery in international markets in which Visa processes the majority of transactions lagged the U.S. in May. Across most of Europe, as well as Australia, Canada and Japan, the trajectory so far is comparable to the U.S. India and Singapore are slowly reopening, said Visa, while a few markets, such as New Zealand, Denmark and Chile, have positive year-over-year constant dollar growth in May.Global processed transactions declined 12% in May, a 12 ppt improvement over April. Since April, the mix has shifted to larger ticket transactions.Cross-border volumes excluding intra-Europe transactions declined 45% in May, a 6 ppt improvement over April. Travel related cross-border volumes declined 78% in May while cross-border eCommerce (excluding travel) continued to grow strongly, up 18%. Cross-border volumes including intra-Europe transactions declined 35% in May, an 8 ppt improvement over April.“As we have indicated before, cross-border volumes excluding intra-Europe transactions drive our international transaction revenues” Visa said.Shares in Visa are currently trading up 3.5% year-to-date, and analysts have a bullish Strong Buy consensus on the stock. In the last three months, 18 analysts have published buy ratings vs 5 hold ratings. Meanwhile the average analyst price target stands at $200 (3% upside potential). (See V stock analysis on TipRanks).RBC Capital analyst Daniel Perlin recently bumped up his price target from $195 to $212 (9% upside potential). “Overall volume trends point to a path of stabilization, while the shape of the recovery likely to be more elongated. However, new secular opportunities in ecommerce & accelerated cash to electronic conversion points to solid long-term growth.” he explained.“Our higher valuation is based on our view that V will be able to expand its constituencies, improve its competitive position, and accelerate secular trends as we emerge into a more normalized phase of growth” the analyst added.Related News: Western Union Seeks To Buy MoneyGram; MGI Spikes 32% Amazon’s Jeff Bezos Invests In UK Freight Startup Beacon Zynga Snaps Up Peak For $1.8B In Its Largest Deal To Date; Shares Up 7% More recent articles from Smarter Analyst: * Free Version of WWE Network Now Available for Fans * Bristol Myers Reveals Positive Results For Ulcerative Colitis Pivotal Trial * Pfizer Embarks On $500 Million Investment Plan For Biotech Businesses * MongoDB Earnings Preview: Analysts Looking For Beat, Raise Quarter

from Yahoo Finance https://ift.tt/36SlOpi